The anti-inflammatory effect of Limosilactobacillus Reuteri b2 administration
Само за регистроване кориснике
2024
Аутори
Lukić, IvanaPopović, Mina
Miljković, Radmila
Tsibulskaya, Darya
Panić, Marko
Dragačević, Luka
Stojanović, Marijana
Конференцијски прилог (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Limosilactobacillus reuteri demonstrates a significant
role in treating gastrointestinal diseases
through the synthesis of various health-promoting
factors. These include mucus-binding proteins,
reactive oxygen species-scavenging enzymes, antimicrobial
agents (reuterin is capable of inhibiting
the growth of a wide spectrum of microorganisms),
vitamins (folate and vitamin B12), and unique
exopolysaccharides. Different strains of L. reuteri
exhibit strain-specific anti-inflammatory effects,
influencing the expression of immune-related
factors such as IL-10 and TNF-α (PMID: 20798357;
PMID: 22207578). Furthermore, the mitigating
impact of L. reuteri strains on inflammation is confirmed
in vivo and in vitro with the implication of
an interaction between probiotics and immune
cells in the intestinal mucosa (PMID: 22207578).
Our study aimed to investigate the potential anti-
inflammatory effects of daily treatment with autochthonous
probiotic strain L. reuteri B2 (PMID:
33...932415) could have an anti-inflammatory effect
on local immune response. In a 14-day experiment
with Intor Swiss: Albino mice (n=10), those treated
with L. reuteri B2 (5x106 CFU/mL, 100 μl) showed a
favorable impact on the gut’s inflammatory environment.
Histological analyses of colon samples
and intraperitoneal macrophages revealed lower
myeloperoxidase (MPO) activity, reduced production
of superoxide ions, IFNγ, IL-6, and TNFα, along
with an enhanced production of IL-10 in L. reuteri
B2 treated mice compared to untreated ones. Notably,
histopathological preparations did not show
significant differences between the groups. The
study suggests that L. reuteri B2 may be valuable
for further evaluation in managing, preventing,
and treating inflammatory bowel diseases. The
presented findings contribute to understanding
the specific anti-inflammatory effects of this strain
on the local immune response, supporting its potential
as a therapeutic agent.
Кључне речи:
Limosilactobacillus reuteri / anti-inflammatory effect / mouse modelИзвор:
XIII Congress of microbiologists of Serbia with international participation, Mikromed regio 5, From biotechnology to human and planetary health, 4-6 april, 2024, 38-38Издавач:
- Serbian Society for Microbiology
Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200177 (Центар за имунолошка истраживања 'Бранислав Јанковић' Торлак, Београд) (RS-MESTD-inst-2020-200177)
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200007 (Универзитет у Београду, Институт за биолошка истраживања 'Синиша Станковић') (RS-MESTD-inst-2020-200007)
Институција/група
TorlakTY - CONF AU - Lukić, Ivana AU - Popović, Mina AU - Miljković, Radmila AU - Tsibulskaya, Darya AU - Panić, Marko AU - Dragačević, Luka AU - Stojanović, Marijana PY - 2024 UR - http://intor.torlakinstitut.com/handle/123456789/874 AB - Limosilactobacillus reuteri demonstrates a significant role in treating gastrointestinal diseases through the synthesis of various health-promoting factors. These include mucus-binding proteins, reactive oxygen species-scavenging enzymes, antimicrobial agents (reuterin is capable of inhibiting the growth of a wide spectrum of microorganisms), vitamins (folate and vitamin B12), and unique exopolysaccharides. Different strains of L. reuteri exhibit strain-specific anti-inflammatory effects, influencing the expression of immune-related factors such as IL-10 and TNF-α (PMID: 20798357; PMID: 22207578). Furthermore, the mitigating impact of L. reuteri strains on inflammation is confirmed in vivo and in vitro with the implication of an interaction between probiotics and immune cells in the intestinal mucosa (PMID: 22207578). Our study aimed to investigate the potential anti- inflammatory effects of daily treatment with autochthonous probiotic strain L. reuteri B2 (PMID: 33932415) could have an anti-inflammatory effect on local immune response. In a 14-day experiment with Intor Swiss: Albino mice (n=10), those treated with L. reuteri B2 (5x106 CFU/mL, 100 μl) showed a favorable impact on the gut’s inflammatory environment. Histological analyses of colon samples and intraperitoneal macrophages revealed lower myeloperoxidase (MPO) activity, reduced production of superoxide ions, IFNγ, IL-6, and TNFα, along with an enhanced production of IL-10 in L. reuteri B2 treated mice compared to untreated ones. Notably, histopathological preparations did not show significant differences between the groups. The study suggests that L. reuteri B2 may be valuable for further evaluation in managing, preventing, and treating inflammatory bowel diseases. The presented findings contribute to understanding the specific anti-inflammatory effects of this strain on the local immune response, supporting its potential as a therapeutic agent. PB - Serbian Society for Microbiology C3 - XIII Congress of microbiologists of Serbia with international participation, Mikromed regio 5, From biotechnology to human and planetary health, 4-6 april T1 - The anti-inflammatory effect of Limosilactobacillus Reuteri b2 administration EP - 38 SP - 38 UR - https://hdl.handle.net/21.15107/rcub_intor_874 ER -
@conference{ author = "Lukić, Ivana and Popović, Mina and Miljković, Radmila and Tsibulskaya, Darya and Panić, Marko and Dragačević, Luka and Stojanović, Marijana", year = "2024", abstract = "Limosilactobacillus reuteri demonstrates a significant role in treating gastrointestinal diseases through the synthesis of various health-promoting factors. These include mucus-binding proteins, reactive oxygen species-scavenging enzymes, antimicrobial agents (reuterin is capable of inhibiting the growth of a wide spectrum of microorganisms), vitamins (folate and vitamin B12), and unique exopolysaccharides. Different strains of L. reuteri exhibit strain-specific anti-inflammatory effects, influencing the expression of immune-related factors such as IL-10 and TNF-α (PMID: 20798357; PMID: 22207578). Furthermore, the mitigating impact of L. reuteri strains on inflammation is confirmed in vivo and in vitro with the implication of an interaction between probiotics and immune cells in the intestinal mucosa (PMID: 22207578). Our study aimed to investigate the potential anti- inflammatory effects of daily treatment with autochthonous probiotic strain L. reuteri B2 (PMID: 33932415) could have an anti-inflammatory effect on local immune response. In a 14-day experiment with Intor Swiss: Albino mice (n=10), those treated with L. reuteri B2 (5x106 CFU/mL, 100 μl) showed a favorable impact on the gut’s inflammatory environment. Histological analyses of colon samples and intraperitoneal macrophages revealed lower myeloperoxidase (MPO) activity, reduced production of superoxide ions, IFNγ, IL-6, and TNFα, along with an enhanced production of IL-10 in L. reuteri B2 treated mice compared to untreated ones. Notably, histopathological preparations did not show significant differences between the groups. The study suggests that L. reuteri B2 may be valuable for further evaluation in managing, preventing, and treating inflammatory bowel diseases. The presented findings contribute to understanding the specific anti-inflammatory effects of this strain on the local immune response, supporting its potential as a therapeutic agent.", publisher = "Serbian Society for Microbiology", journal = "XIII Congress of microbiologists of Serbia with international participation, Mikromed regio 5, From biotechnology to human and planetary health, 4-6 april", title = "The anti-inflammatory effect of Limosilactobacillus Reuteri b2 administration", pages = "38-38", url = "https://hdl.handle.net/21.15107/rcub_intor_874" }
Lukić, I., Popović, M., Miljković, R., Tsibulskaya, D., Panić, M., Dragačević, L.,& Stojanović, M.. (2024). The anti-inflammatory effect of Limosilactobacillus Reuteri b2 administration. in XIII Congress of microbiologists of Serbia with international participation, Mikromed regio 5, From biotechnology to human and planetary health, 4-6 april Serbian Society for Microbiology., 38-38. https://hdl.handle.net/21.15107/rcub_intor_874
Lukić I, Popović M, Miljković R, Tsibulskaya D, Panić M, Dragačević L, Stojanović M. The anti-inflammatory effect of Limosilactobacillus Reuteri b2 administration. in XIII Congress of microbiologists of Serbia with international participation, Mikromed regio 5, From biotechnology to human and planetary health, 4-6 april. 2024;:38-38. https://hdl.handle.net/21.15107/rcub_intor_874 .
Lukić, Ivana, Popović, Mina, Miljković, Radmila, Tsibulskaya, Darya, Panić, Marko, Dragačević, Luka, Stojanović, Marijana, "The anti-inflammatory effect of Limosilactobacillus Reuteri b2 administration" in XIII Congress of microbiologists of Serbia with international participation, Mikromed regio 5, From biotechnology to human and planetary health, 4-6 april (2024):38-38, https://hdl.handle.net/21.15107/rcub_intor_874 .